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Background
Oncolytic adenoviruses (OAds) demonstrated great
potential for the treatment of cancer in many pre-clinical
studies. The pre-existing immunity and their immunodo-
minance, however, still limit the success of oncolytic vir-
otherapy in cancer patients. Thus, a transition from
1University of Helsinki, Helsinki, Finland
Full list of author information is available at the end of the article
Figure 1
Capasso et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P333
http://www.immunotherapyofcancer.org/content/3/S2/P333
© 2015 Capasso et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
oncolytic agents to oncolytic vaccines seems to be neces-
sary, since the involment of the immune system may play
a key role in the efficacy of OAds.
Methods
Therefore, we developed a new oncolytic vaccine platform
that uses the virus as adjuvant for MHC-I tumor epitopes
that are loaded onto the viral capsid via electrostatic inter-
actions. By using the model epitope SIINFEKL, we studied
the efficacy of the peptide-coated conditionally replicating
adenoviruses (PeptiCRAds) in immunocompetent mice
bearing B16-OVA melanomas.
Results
We found that OVA-targeting PeptiCRAds significantly
reduced the tumor growth compared to controls (Figure 1)
and elicited larger SIINFEKL-specific CD8 responses.
Furthermore, we observed an increased presence of mature
and epitope-specific dendritic cells in the spleens of mice
treated with PeptiCRAd suggesting a modulating effect on
antigen presenting cells. Next, we demonstrated that a Pep-
tiCRAd targeting both TRP-2 and gp100 tumor antigens
could elicit a broad immunological response able to signifi-
cantly reduce the tumor growth of treated and, most
importantly, untreated B16-F10 melanomas (Figure 2 A, B).
Finally, for the first time, immune deficient mice bearing
human melanomas and engrafted with a human immune
system were used to study the synergy between oncolytic
activity and immunogenicity of oncolytic adenoviruses.
A MAGE-A1-targeting PeptiCRAd, encoding for granulo-
cyte-macrophage colony stimulating factor, was able to era-
dicate human melanomas and increased the percentage of
human MAGE-A1-CD8 T cells compared to the naked
OAd.
Conclusions
In conclusion, we demonstrated that the immunogeni-
city of OAds can be exploited to drive the immune
response towards choosen epitopes and that this
approach allows for rapid re-targeting without the need
of genetic modifications, making PeptiCRAds a suitable
platform for the next generation of highly personalized
cancer vaccine immunotherapies.
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